Fremanezumab is a humanized monoclonal antibody targeting calcitonin gene–related peptide (CGRP). It is administered monthly via SQ injection.
In this NEJM study, fremanezumab was effective as a preventive treatment for chronic migraine: http://www.nejm.org/doi/full/10.1056/NEJMoa1709038
No comments:
Post a Comment